New Test Predicts Risk of Cardiovascular Disease
Ann Arbor, Michigan, USA/Feb 13, 2017
A new technology that predicts an individual’s risk for developing cardiovascular disease has been launched today by Everist Health Inc of Ann Arbor, Michigan. “Eighteen million people die every year from cardiovascular disease,“ says Everist Health CEO Matt Bartlam. “It is the world’s number one killer. I believe our test can make a major contribution to improving the world’s cardiovascular health for several reasons.
“First, the test is non-invasive, painless and produces results in under twenty minutes. The results provide medical professionals with important new data on one’s current cardiovascular health that, at the same time, is translated into simple numbers that we can all use and understand
“The new test uses elements of pulse wave analysis and plesmography to measure the flexibility of a person’s arteries which is recognized as a very good predictor of future risk. A device, known as AngioDefender™, measures the percentage flow mediated dilation (FMD) of a patient’s arteries- the ability of arteries to contract and expand. This reading, together with other basic patient details such as: age, blood glucose levels and cholesterol levels can then be used to quickly calculate a person’s heart and cardiovascular age.
“So, while the medical professional gets new and very important medical data -the FMD score, the individual can have their medical assessment translated into a simple heart age number that is easy to understand and relate to. If an individual’s heart age turns out to be lower than their actual age the message is to continue doing the things that are contributing to a healthy cardiovascular system such as diet, exercise and non-smoking – but if the heart age is higher than a person’s chronological age, this can be a powerful driver of behavior change to lower the risk of a heart attack or stroke.
“Although there are other ways of estimating an individual heart age, it is important to recognize that our method permits a personal calculation based on the individual’s actual medical information rather than on general historical population data,” says Matt Bartlam.
Importantly, the AngioDefender™ test can reveal cardiovascular problems in people that may appear to be at low risk such as athletes or young apparently fit, non- smokers with a healthy lifestyle. So called asymptomatic people.
Everist Health believes that this new test can have wide applications because it is light, mobile and does not require a specially trained operator. “It can be made available to the public in a variety of non- hospital environments . We have conducted many successful tests in Canada, Europe and India and it has been shown to work well in several different markets. For example, the health testing of transport workers in their workplace in Mumbai, India, and corporate wellness program, community care facilities and rehabilitation centres in Canada.
“At the same time researchers in the UK National Health Service are using the technology in trials where new cancer drugs are being monitored for potential cardiovascular side effects.
“Eventually I believe our technology will find wide application globally, including in countries where the hospital systems are poorly developed,” says Matt Bartlam who points out that interest has been shown by health workers in Africa.
Initially the new technology will be available in Germany, the UK, Canada and India where multiple trials are ongoing and distributors are in place. The company has immediate plans to broaden availability to Austria, Switzerland, Australia and, by 2018, the entire European Union. The technology has also been the subject of trials in the USA which have recently been concluded. “We expect to submit our findings to the FDA in the next few months,” says Matt Bartlam.